Potential uses of naltrexone in emergency department patients with opioid use disorder

References

• An Act relative to substance use, treatment, education and prevention, 4056 (2015–2016).
   Google Scholar
• Vivolo-Kantor AM, Seth P, Gladden RM, et al. Vital signs: trends in emergency department visits for suspected opioid overdoses—United States, July 2016–September 2017. MMWR Morb Mortal Wkly Rep. 2018;67:279.
   PubMed Web of Science ®Google Scholar
• National Center for Health Statistics. Drugs involved in U.S. overdose deaths, 1999 to 2017. 2018;1–13.
   Google Scholar
• Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician. 2014;17:E119–E128.
   PubMed Web of Science ®Google Scholar
• Peterson AB, Gladden RM, Delcher C, et al. Increases in fentanyl-related overdose deaths - Florida and Ohio, 2013-2015. MMWR Morb Mortal Wkly Rep. 2016;65:844–849.
   PubMed Web of Science ®Google Scholar
• Inocencio TJ, Carroll NV, Read EJ, et al. The economic burden of opioid-related poisoning in the United States. Pain Med. 2013;14:1534–1547.
   PubMed Web of Science ®Google Scholar
• D’Onofrio G, O’Connor PG, Pantalon MV, et al. Emergency department–initiated buprenorphine/naloxone treatment for opioid dependence. JAMA. 2015;313:1636–1639.
   PubMed Web of Science ®Google Scholar
• Kjome KL, Moeller FG. Long-acting injectable naltrexone for the management of patients with opioid dependence. Subs Abuse Res Treatment. 2011;5:1–9.
   Google Scholar
• Tetrault JM, Fiellin DA. Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs. 2012;72:217–228.
   PubMed Web of Science ®Google Scholar
• Duramed Pharmaceuticals Inc. Product information: REVIA(R) oral tablets, naltrexone HCl oral tablets. Pomona (NY):Duramed Pharmaceuticals; 2013.
   Google Scholar
• Rawson RA, McCann MJ, Hasson AJ, et al. Addiction pharmacotherapy 2000: new options, new challenges. J Psychoactive Drugs. 2000;32:371–378.
   PubMed Web of Science ®Google Scholar
• Emmerson PJ, Liu MR, Woods JH, et al. Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther. 1994;271:1630–1637.
   PubMed Web of Science ®Google Scholar
• Weerts EM, Kim YK, Wand GS, et al. Differences in delta- and mu-opioid receptor blockade measured by positron emission tomography in naltrexone-treated recently abstinent alcohol-dependent subjects. Neuropsychopharmacology. 2008;33:653–665.
   PubMed Web of Science ®Google Scholar
• Yancey-Wrona J, Dallaire B, Bilsky E, et al. 6beta-naltrexol, a peripherally selective opioid antagonist that inhibits morphine-induced slowing of gastrointestinal transit: an exploratory study. Pain Med. 2011;12:1727–1737.
   PubMed Web of Science ®Google Scholar
• Porter SJ, Somogyi AA, White JM. Kinetics and inhibition of the formation of 6beta-naltrexol from naltrexone in human liver cytosol. Br J Clin Pharmacol. 2000;50:465–471.
   PubMed Web of Science ®Google Scholar
• Meyer MC, Straughn AB, Lo MW, et al. Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry. 1984;45:15–19.
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210–218.
   PubMed Web of Science ®Google Scholar
• Alkermes, Inc. Product information: VIVITROL(R) intramuscular injection extended-release suspension, naltrexone intramuscular injection extended-release suspension. Waltham (MA): Alkermes, Inc.; 2013.
   Google Scholar
• Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375:357–368.
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Cochrane Drugs and Alcohol Group, editor, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;72:59–27.
   Google Scholar
• Mattick RP, Breen C, Kimber J, Cochrane Drugs and Alcohol Group, editor, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;66:111–163.
   Google Scholar
• Sigmon SC, C Meyer A, Hruska B, et al. Bridging waitlist delays with interim buprenorphine treatment: initial feasibility. Addict Behav. 2015;51:136–142.
   PubMed Web of Science ®Google Scholar
• Jones CM, Campopiano M, Baldwin G, et al. National and state treatment need and capacity for opioid agonist medication-assisted treatment. Am J Public Health. 2015;105:e55–e63.
   PubMed Web of Science ®Google Scholar
• Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry. 1973;28:784–791.
   PubMed Web of Science ®Google Scholar
• Preston KL, Bigelow GE. Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers. J Pharmacol Exp Ther. 1993;264:813–823.
   PubMed Web of Science ®Google Scholar
• Klein JW. Pharmacotherapy for substance use disorders. Med Clin North Am. 2016;100:891–910.
   PubMed Web of Science ®Google Scholar
• Kleber HD. Pharmacologic treatments for heroin and cocaine dependence. Am J Addict. 2003;12:S5–S18.
   PubMed Web of Science ®Google Scholar
• Lee MC, Wagner HNJ, Tanada S, et al. Duration of occupancy of opiate receptors by naltrexone. J Nucl Med. 1988;29:1207–1211.
   PubMed Web of Science ®Google Scholar
• Krupitsky EM, Zvartau EE, Masalov DV, et al. Naltrexone with or without fluoxetine for preventing relapse to heroin addiction in St. Petersburg, Russia. J Subs Abuse Treatment. 2006;31:319–328.
   PubMed Web of Science ®Google Scholar
• Dijkstra BA, De Jong CA, Bluschke SM, et al. Does naltrexone affect craving in abstinent opioid-dependent patients? Addict Biol. 2007;12:176–182.
   PubMed Web of Science ®Google Scholar
• Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31:207–225.
   PubMed Web of Science ®Google Scholar
• Digiusto E, Shakeshaft A, Ritter A, et al. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD). Addiction. 2004;99:450–460.
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Larney S, Kimber J, et al. Excess mortality among opioid-using patients treated with oral naltrexone in Australia. Drug Alcohol Rev. 2015;34:90–96.
   PubMed Web of Science ®Google Scholar
• Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Revs. 2007;26:405–410.
   PubMed Web of Science ®Google Scholar
• Davoli M, Bargagli AM, Perucci CA, for the VEdeTTE Study Group, et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addiction. 2007;102:1954–1959.
   PubMed Web of Science ®Google Scholar
• Larney S, Gowing L, Mattick RP, et al. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug Alcohol Rev. 2014;33:115–128.
   PubMed Web of Science ®Google Scholar
• Tanum L, Solli KK, Latif Z-E-H, et al. The effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence. JAMA Psychiatry. 2017;74:1197–1205.
   Google Scholar
• Kunoe N, Opheim A, Solli KK, et al. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). BMC Pharmacol Toxicol. 2016;17:18.
   PubMed Web of Science ®Google Scholar
• Hollister LE, Schwin RL, Kasper P. Naltrexone treatment of opiate-dependent persons. Drug Alcohol Depend. 1977;2:203–209.
   PubMed Web of Science ®Google Scholar
• Sullivan MA, Rothenberg JL, Vosburg SK, et al. Predictors of retention in naltrexone maintenance for opioid dependence: analysis of a stage I trial. Am J Addict. 2006;15:150–159.
   PubMed Web of Science ®Google Scholar
• Ahamad K, Milloy MJ, Nguyen P, et al. Factors associated with willingness to take extended release naltrexone among injection drug users. Addict Sci Clin Practice. 2015;10:12.
   PubMed Web of Science ®Google Scholar
• Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Minozzi S, editor. The Cochrane database of systematic reviews. Chichester, UK: John Wiley & Sons, Ltd; 2011; p. CD001333.
   Google Scholar
• Volkow ND, Frieden TR, Hyde PS, et al. Medication-assisted therapies-tackling the opioid-overdose epidemic. N Engl J Med. 2014;370:2063–2066.
   PubMed Web of Science ®Google Scholar
• O'Brien CP. A 50-year-old woman addicted to heroin: review of treatment of heroin addiction. JAMA. 2008;300:314–321.
   PubMed Web of Science ®Google Scholar
• Merlo LJ, Greene WM, Pomm R. Mandatory naltrexone treatment prevents relapse among opiate-dependent anesthesiologists returning to practice. J Addict Med. 2011;5:279–283.
   PubMed Web of Science ®Google Scholar
• Krupitsky E, Zvartau E, Woody G. Use of naltrexone to treat opioid addiction in a country in which methadone and buprenorphine are not available. Curr Psychiatry Rep. 2010;12:448–453.
   PubMed Web of Science ®Google Scholar
• Gowing L, Ali R, White JM. Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database Syst Rev. 2017;5:Cd002021.
   PubMedGoogle Scholar
• Yeo M, Campbell V, Bonomo Y, et al. Acute opioid withdrawal on accidental injection of naltrexone. J Paediatr Child Health. 2003;39:315–317.
   PubMed Web of Science ®Google Scholar
• Hassanian-Moghaddam H, Afzali S, Pooya A. Withdrawal syndrome caused by naltrexone in opioid abusers. Hum Exp Toxicol. 2014;33:561–567.
   PubMed Web of Science ®Google Scholar
• Lubman D, Koutsogiannis Z, Kronborg I. Emergency management of inadvertent accelerated opiate withdrawal in dependent opiate users. Drug Alcohol Rev. 2003;22:433–436.
   PubMed Web of Science ®Google Scholar
• Franchitto N, Jullian B, Salles J, et al. Management of precipitated opiate withdrawal syndrome induced by nalmefene mistakenly prescribed in opiate-dependent patients: a review for clinicians. Expert Opin Drug Metab Toxicol. 2017;13:669–677.
   PubMed Web of Science ®Google Scholar
• Donnerstag N, Schneider T, Luthi A, et al. Severe opioid withdrawal syndrome after a single dose of nalmefene. Eur J Clin Pharmacol. 2015;71:1025–1026.
   PubMed Web of Science ®Google Scholar
• Elman I, D'Ambra MN, Krause S, et al. Ultrarapid opioid detoxification: effects on cardiopulmonary physiology, stress hormones and clinical outcomes. Drug Alcohol Depend. 2001;61:163–172.
   PubMed Web of Science ®Google Scholar
• Lorenzi P, Marsili M, Boncinelli S, et al. Searching for a general anaesthesia protocol for rapid detoxification from opioids. Eur J Anaesthesiol. 1999;16:719–727.
   PubMed Web of Science ®Google Scholar
• Gold CG, Cullen DJ, Gonzales S, et al. Rapid opioid detoxification during general anesthesia: a review of 20 patients. Anesthesiology. 1999;91:1639–1647.
   PubMed Web of Science ®Google Scholar
• Hensel M, Wolter S, Kox WJ. EEG controlled rapid opioid withdrawal under general anaesthesia. Brit J Anaesth. 2000;84:236–238.
   PubMed Web of Science ®Google Scholar
• Lawental E. Ultra rapid opiate detoxification as compared to 30-day inpatient detoxification program–a retrospective follow-up study. J Subs Abuse. 2000;11:173–181.
   PubMedGoogle Scholar
• McGregor C, Ali R, White JM, et al. A comparison of antagonist-precipitated withdrawal under anesthesia to standard inpatient withdrawal as a precursor to maintenance naltrexone treatment in heroin users: outcomes at 6 and 12 months. Drug Alcohol Depend. 2002;68:5–14.
   PubMed Web of Science ®Google Scholar
• Collins ED, Kleber HD, Whittington RA, et al. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA. 2005;294:903–913.
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Cohen H, Atias S. Outcomes of naltrexone maintenance following ultra rapid opiate detoxification versus intensive inpatient detoxification. Am J Addict. 2002;11:52–56.
   PubMed Web of Science ®Google Scholar
• Favrat B, Zimmermann G, Zullino D, et al. Opioid antagonist detoxification under anaesthesia versus traditional clonidine detoxification combined with an additional week of psychosocial support: a randomised clinical trial. Drug Alcohol Depend. 2006;81:109–116.
   PubMed Web of Science ®Google Scholar
• Singh J, Basu D. Ultra-rapid opioid detoxification: current status and controversies. J Postgrad Med. 2004;50:227–232.
   PubMedGoogle Scholar
• Armstrong J. Emergency department presentations of naltrexone-accelerated detoxification. Acad Emerg Med. 2003;10:860–866.
   PubMed Web of Science ®Google Scholar
• Pfab R, Pfab R, Hirtl C, et al. Opiate detoxification under anesthesia: no apparent benefit but suppression of thyroid hormones and risk of pulmonary and renal failure. J Toxicol Clin Toxicol. 1999;37:43–50.
   PubMed Web of Science ®Google Scholar
• Gowing L, Ali R, White J. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Gowing L, editor. The Cochrane database of systematic reviews. 2006 ed. Chichester, UK: John Wiley & Sons, Ltd; 2006;294:CD002022.
   Google Scholar
• Krupitsky E, Zvartau E, Blokhina E, et al. Randomized trial of long-acting sustained-release naltrexone implant vs oral naltrexone or placebo for preventing relapse to opioid dependence. Arch Gen Psychiatry. 2012;69:973–981.
   PubMed Web of Science ®Google Scholar
• Lee JD, Nunes EV J, Novo P et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018 Jan;391:309–318.
   PubMed Web of Science ®Google Scholar
• Kunoe N, Lobmaier P, Vederhus JK, et al. Challenges to antagonist blockade during sustained-release naltrexone treatment. Addiction. 2010;105:1633–1639.
   PubMed Web of Science ®Google Scholar
• Kruptisky EM, Burakov AM, Tsoy MV, et al. Overcoming opioid blockade from depot naltrexone (Prodetoxon). Addiction. 2007;102:1164–1165.
   PubMed Web of Science ®Google Scholar
• Griswold MK, Chai PR, Krotulski AJ, et al. Self-identification of nonpharmaceutical fentanyl exposure following heroin overdose. Clin Toxicol. 2018;56:37–42.
   PubMed Web of Science ®Google Scholar
• Saucier R, Wolfe D, Dasgupta N. Review of Case Narratives from Fatal Overdoses Associated with Injectable Naltrexone for Opioid Dependence. Drug Safety. 2018 Oct;41:981–988.
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018;169:137–110.
   PubMed Web of Science ®Google Scholar
• Kennedy J, Dipzinski A, Roll J, et al. Medicare prescription drug plan coverage of pharmacotherapies for opioid and alcohol dependence in WA. Drug Alcohol Depend. 2011;114:201–206.
   PubMed Web of Science ®Google Scholar
• Saxon AJ, Akerman SC, Liu C-C, et al. Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: vivitrol's cost and treatment outcomes registry. Addiction. 2018;113:1477–1487.
   PubMed Web of Science ®Google Scholar
• Tretter F, Burkhardt D, Bussello-Spieth B, et al. Clinical experience with antagonist-induced opiate withdrawal under anaesthesia. Addiction. 1998;93:269–275.
   PubMed Web of Science ®Google Scholar
• Hensel M, Kox WJ. Safety, efficacy, and long-term results of a modified version of rapid opiate detoxification under general anaesthesia: a prospective study in methadone, heroin, codeine and morphine addicts. Acta Anaesthesiol Scand. 2000;44:326–333.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Patkar AA, Peindl K, et al. Early outcomes following low dose naltrexone enhancement of opioid detoxification. Am J Addict. 2009;18:109–116.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Gottheil E, Buonanno A, et al. Use of very low-dose naltrexone during opiate detoxification. J Addict Dis. 2003;22:63–70.
   PubMed Web of Science ®Google Scholar
• Olmstead MC, Burns LH. Ultra-low-dose naltrexone suppresses rewarding effects of opiates and aversive effects of opiate withdrawal in rats. Psychopharmacology. 2005;181:576–581.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Patkar AA, Peindl K, et al. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence. J Clin Psychopharmacol. 2007;27:468–474.
   PubMed Web of Science ®Google Scholar
• Ko MC, Divin MF, Lee H, et al. Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey. J Pharmacol Exp Ther. 2006;316:772–779.
   PubMed Web of Science ®Google Scholar
• Raehal KM, Lowery JJ, Bhamidipati CM, et al. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. J Pharmacol Exp Ther. 2005;313:1150–1162.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Wu LT, Peindl KS, et al. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial. Drug Alcohol Depend. 2014;138:83–88.
   PubMed Web of Science ®Google Scholar
• Mannelli P, Patkar AA, Peindl K, et al. Very low dose naltrexone addition in opioid detoxification: a randomized, controlled trial. Addict Biol. 2009;14:204–213.
   PubMed Web of Science ®Google Scholar
• Bisaga A, Mannelli P, Yu M, et al. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder_ A phase 3 randomized trial. Drug Alcohol Depend. 2018;187:171–178.
   PubMed Web of Science ®Google Scholar